On June 30, 2021, Tonghua Dongbao announced that Dongbao Zixing, a wholly-owned subsidiary, and Shanghai WuXi AppTec New Drug R&D Company (hereinafter referred to as "Shanghai WuXi") signed the "Technology Transfer Contract for THDB130/THDB131 Class I New Drug Research and Development Projects" on June 30, 2021, stipulating that Dongbao Zixing entrusted Shanghai WuXi Xing to submit an application for clinical declaration to the Drug Evaluation Center of the State Drug Administration through its designated affiliates. On December 15, 2021, As a principal, Dongbao Zixing received a drug clinical trial approval notice for URAT1 inhibitors (THDBH130 tablets) issued by the Drug Evaluation Center of the State Drug Administration. The approved indications for Tonghua Toho's THDBH130 product are hyperuricemia and gout.
![Tonghua Dongbao class of new drug URAT1 inhibitors declared clinical trials approved[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)